Animal Studies Show CRISPR Therapy Achieves Three-Year Lipid Control with a Single Infusion
2 day ago / Read about 0 minute
Author:小编   

Scientists at Verve Therapeutics, a subsidiary of Eli Lilly, have developed a CRISPR base-editing therapy, with results published in Nature. Experiments in cynomolgus monkeys show that a single infusion can sustainably control lipid levels for three years, offering patients a new path to free themselves from daily medication.